论文部分内容阅读
目的探讨孕中期母血清筛查Freeβ-HCG单指标MOM值与染色体异常疾病的相关性。方法应用时间分辨荧光免疫方法 (DELFIA)检测宁波地区73 379例孕中期母血清标记物Freeβ-HCG,将其MOM值根据数值大小分成五组,比较其染色体异常疾病的发生率。结果 73 379例孕妇中A组有5854例,其中21三体发生率为3.8‰,18三体没有发现,其他染色体病发生率为4.8‰。B组有4348例,其中21三体发生率为0.5‰,18三体发生率为0.2‰,其他染色体病发生率为0.2‰。C组有55 742例,其中21三体发生率为0.1‰,18三体发生率为0.01‰,其他染色体病发生率为0.09‰。D组有6426例,其中21三体没有发现,18三体发生率为0.2‰,其他染色体病没有发现。E组有1009例,其中21三体没有发现,18三体发生率为5.9‰,其他染色体病发生率为2‰。A组21三体综合征和其他染色体异常疾病的发生率最高。E组18三体综合征的发生率最高。结论产前筛查Freeβ-HCG MOM异常结果,对于21三体,18三体综合征及其它染色体异常疾病均有一定的预测意义,应加强这部分人群的监测和保健指导,尤其是Free-HCG MOM>2.5和MOM<0.3的结果。
Objective To investigate the correlation between MOM value of single β-HCG screening and maternal chromosomal abnormalities in second trimester maternal serum screening. Methods 73 379 maternal serum markers of Freeβ-HCG in Ningbo were detected by time-resolved immunofluorescence assay (DELFIA). The MOM values were divided into five groups according to their numerical values. The incidence of chromosomal abnormalities was compared. Results In 73 379 pregnant women, there were 5854 cases in group A, of which the incidence of trisomy 21 was 3.8 ‰, trisomy 18 was not found, and the incidence of other chromosome diseases was 4.8 ‰. There were 4348 cases in group B, of which the incidence of trisomy 21 was 0.5 ‰, the incidence of trisomy 18 was 0.2 ‰, and the incidence of other chromosome diseases was 0.2 ‰. There were 55 742 cases in group C, in which the incidence of trisomy 21 was 0.1 ‰, the incidence of trisomy 18 was 0.01 ‰, and the incidence of other chromosome diseases was 0.09 ‰. There were 6426 cases in group D, of which trisomy 21 was not found, trisomy 18 was 0.2% o, and other chromosomal diseases were not found. There were 1009 cases in group E, of which trisomy 21 was not found, the incidence of trisomy 18 was 5.9 ‰, and the incidence of other chromosome diseases was 2 ‰. A group of 21 trisomy syndrome and other chromosomal abnormalities the highest incidence. E group 18 trisomy syndrome the highest incidence. Conclusions The abnormal results of prenatal screening for Freeβ-HCG MOM have certain predictive value for trisomy 21, trisomy 18 and other chromosomal abnormalities. Monitoring and health care guidance should be strengthened in this part of the population, especially Free-HCG MOM> 2.5 and MOM <0.3 results.